⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15086576 | 0.77 | TSHR (0.33) | — | |
| SCHEMBL11905959 | 0.74 | — | — | |
| SCHEMBL12501757 | 0.72 | TSHR (0.32) | — | |
| SCHEMBL4445846 | 0.70 | — | — | |
| SCHEMBL10433392 | 0.69 | — | — | |
| SCHEMBL16085224 | 0.69 | — | — | |
| SCHEMBL5828432 | 0.69 | — | — | |
| SCHEMBL8936395 | 0.69 | — | — | |
| SCHEMBL8936452 | 0.69 | — | — | |
| SCHEMBL686782 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1889840-A1 | Rearrangement of spirolactams | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-02-20 | — | — | EP | claimed |
| WO-2008009695-A1 | REARRANGEMENT OF SPIROLACTAMS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-01-24 | — | — | WO | claimed |
| US-9988417-B2 | Process for the preparation of estetrol | CRYSTAL PHARMA, S.A.U. (ES) | 2018-06-05 | — | — | US | disclosed |
| EP-2855421-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3,3-DIPHENYLPROPYLAMINES | CRYSTAL PHARMA SAU (ES) | 2018-03-21 | — | — | EP | disclosed |
| US-20180056270-A1 | AMYLOSE DERIVATIVE AND OPTICAL ISOMER SEPARATING AGENT CONTAINING SAME | DAICEL CORPORATION (JP) | 2018-03-01 | — | — | US | disclosed |
| US-9901902-B1 | Amylose derivative and optical isomer separating agent containing same | DAICEL CORPORATION (JP) | 2018-02-27 | — | — | US | disclosed |
| US-20170240558-A1 | SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3046928-B1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA SAU (ES) | 2017-02-08 | — | — | EP | disclosed |
| US-20160340298-A1 | NOVEL COMPOUNDS | AVANTI POLAR LIPIDS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9422228-B2 | Process for the preparation of optically pure fesoterodine derivatives | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-23 | — | — | US | disclosed |
| US-20160229885-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-11 | — | — | US | disclosed |
| EP-1676836-A1 | Regioselective hydroxylation, functionalisation and protection of spirolactams II | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006065357-A1 | METHOD OF MAKING NANOCOMPOSITES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128867-A1 | Method of making composites and nanocomposites | 3M INNOVATIVE PROPERTIES COMPANY | 2006-06-15 | — | — | US | disclosed |
| US-20050261492-A1 | Regioselective hydroxylation, functionalisation and protection of spirolactams | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2005-11-24 | — | — | US | disclosed |
| EP-1598336-A1 | Regioselective hydroxylation, functionalisation and protection of spirolactams | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005108357-A1 | REGIOSELECTIVE FUNCTIONALISATION AND PROTECTION OF SPIROLACTAMS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108356-A1 | SPIROLACTAMS AND THEIR SYNTHESIS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-11-17 | — | — | WO | disclosed |
| EP-0847399-A1 | NOVEL ESTROGENS | Astra Aktiebolag (SE) | 1998-06-17 | — | — | EP | disclosed |
| WO-1997008188-A1 | NOVEL ESTROGENS | ASTRA AKTIEBOLAG (SE) | 1997-03-06 | — | — | WO | disclosed |